JAMA
Original Investigation
April 8, 2024
Steven E.ÌýNissen,ÌýMD; KathyÌýWolski,ÌýMPH; Gerald F.ÌýWatts,ÌýMD, DSc; Michael J.ÌýKoren,ÌýMD; HenryÌýFok,ÌýMBBS, PhD; Stephen J.ÌýNicholls,ÌýMBBS, PhD; David A.ÌýRider,ÌýPhD; LeslieÌýCho,ÌýMD; StevenÌýRomano,ÌýMD; CarrieÌýMelgaard,ÌýMS; CurtisÌýRambaran,ÌýMBBS, MD
JAMA. 2024; 331(18):1534-1543. 10.1001/jama.2024.4504
This phase 1 randomized study assesses the safety and tolerability of zerlasiran, a short interfering RNA targeting hepatic synthesis of apolipoprotein(a), and its effects on serum concentrations of lipoprotein(a), in healthy participants and patients with stable atherosclerotic cardiovascular disease.